Skip to main content

Table 3 Multivariate analysis

From: Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT

 

HR

CI

p

LFS

 MUD vs Haplo

0.94

0.76–1.17

0.630

 Year of Tx

1.01

0.98–1.03

0.445

 Age (per 10 years)

1.10

0.95–1.27

0.173

 Status at Tx

  CR ≥ 2 vs CR1

1.22

1.05–1.42

0.009

  Advanced vs CR1

1.67

1.48–1.89

< 10− 4

 Cytogenetics

  Intermediate vs good

1.10

0.76–1.60

0.590

  Poor vs good

1.79

1.25–2.56

0.001

  Secondary vs good

1.49

1.06–2.08

0.019

  Missing vs good

1.40

1.01–1.95

0.043

 Female D/male R

1.09

0.93–1.27

0.247

 KPS ≥ 90%

0.85

0.76–0.96

0.009

 PBSC vs BM

1.04

0.86–1.25

0.670

 In vivo TCD

0.93

0.82–1.05

0.288

 Previous autograft

1.36

1.00–1.86

0.045

 RIC vs MAC

1.04

0.92–1.18

0.468

 Center (frailty)

  

0.292

OS

 MUD vs Haplo

0.87

0.68–1.10

0.244

 Year of Tx

1.01

0.98–1.04

0.392

 Age (per 10 years)

1.16

1.00–1.34

0.046

 Status at Tx

  CR ≥ 2 vs CR1

1.16

0.99–1.37

0.059

  Advanced vs CR1

1.62

1.42–1.85

< 10−4

 Cytogenetics

  Intermediate vs good

1.05

0.71–1.54

0.792

  Poor vs good

1.66

1.14–2.40

0.007

  Secondary vs good

1.40

0.99–1.98

0.057

  Missing vs good

1.32

0.94–1.87

0.105

 Female D/male R

1.14

0.97–1.34

0.093

 KPS ≥ 90%

0.83

0.74–0.94

0.003

 PBSC vs BM

1.01

0.83–1.24

0.893

 in vivo TCD

0.93

0.81–1.08

0.372

 Previous autograft

1.39

1.00–1.93

0.043

 RIC vs MAC

1.12

0.97–1.28

0.096

 Center (frailty)

  

0.062

RI

 MUD vs Haplo

1.06

0.76–1.47

0.699

 Year of Tx

0.99

0.96–1.03

0.790

 Age (per 10 years)

0.87

0.71–1.08

0.230

 Status at Tx

  CR ≥ 2 vs CR1

1.26

1.01–1.57

0.033

  Advanced vs CR1

1.96

1.65–2.34

< 10−4

 Cytogenetics

  Intermediate vs good

0.95

0.57–1.60

0.869

  Poor vs good

2.11

1.29–3.43

0.002

  Secondary vs good

1.35

0.85–2.14

0.202

  Missing vs good

1.31

0.83–2.06

0.241

 Female D/male R

0.88

0.69–1.11

0.285

 KPS ≥ 90%

0.96

0.82–1.14

0.711

 PBSC vs BM

1.02

0.77–1.34

0.865

 in vivo TCD

1.04

0.86–1.25

0.662

 Previous autograft

1.16

0.71–1.88

0.546

 RIC vs MAC

0.91

0.76–1.10

0.374

 Center (frailty)

  

0.135

NRM

 MUD vs Haplo

0.75

0.54–1.05

0.095

 Year of Tx

1.02

0.98–1.06

0.243

 Age (per 10 years)

1.34

1.10–1.63

0.003

 Status at Tx

  CR ≥ 2 vs CR1

1.18

0.94–1.47

0.135

  Advanced vs CR1

1.45

1.21–1.74

< 10−4

 Cytogenetics

  Intermediate vs good

1.29

0.75–2.22

0.353

  Poor vs good

1.46

0.84–2.51

0.172

  Secondary vs good

1.63

0.99–2.68

0.051

  Missing vs good

1.49

0.91–2.43

0.111

 Female D/male R

1.34

1.08–1.65

0.005

 KPS ≥ 90%

0.75

0.63–0.89

0.001

 PBSC vs BM

1.08

0.82–1.43

0.564

 In vivo TCD

0.85

0.70–1.04

0.122

 Previous autograft

1.62

1.07–2.46

0.022

 RIC vs MAC

1.19

0.98–1.43

0.066

 Center (frailty)

  

0.015

GRFS

 MUD vs Haplo

1.18

0.95–1.47

0.125

 Year of Tx

0.99

0.97–1.02

0.792

 Age (per 10 years)

1.03

0.90–1.18

0.606

 Status at Tx

  CR ≥ 2 vs CR1

1.16

1.00–1.34

0.038

  Advanced vs CR1

1.64

1.45–1.84

< 10−4

 Cytogenetics

  Intermediate vs good

1.24

0.87–1.75

0.223

  Poor vs good

1.69

1.20–2.38

0.002

  Secondary vs good

1.52

1.11–2.09

0.008

  Missing vs good

1.45

1.06–1.98

0.019

 Female D/male R

1.05

0.90–1.21

0.516

 KPS ≥ 90%

0.85

0.76–0.94

0.003

 PBSC vs BM

1.09

0.91–1.32

0.313

 In vivo TCD

0.75

0.66–0.85

< 10−4

 Previous autograft

1.32

0.97–1.80

0.072

 RIC vs MAC

1.00

0.88–1.13

0.933

 Center (frailty)

  

0.093

aGVHD II–IV

 MUD vs Haplo

1.17

0.82–1.65

0.374

 Year of Tx

1.00

0.96–1.04

0.845

 Age (per 10 years)

0.89

0.71–1.11

0.326

 Status at Tx

  CR ≥ 2 vs CR1

1.00

0.79–1.27

0.942

  advanced vs CR1

1.15

0.95–1.40

0.135

 Cytogenetics

  Intermediate vs good

1.34

0.77–2.34

0.296

  Poor vs good

1.45

0.83–2.53

0.180

  Secondary vs good

1.40

0.84–2.34

0.192

  Missing vs good

1.30

0.78–2.16

0.303

 Female D/male R

1.10

0.88–1.39

0.378

 KPS ≥ 90%

0.87

0.73–1.05

0.152

 PBSC vs BM

1.01

0.75–1.35

0.954

 In vivo TCD

0.70

0.57–0.85

0.001

 Previous autograft

2.18

1.42–3.36

< 10−4

 RIC vs MAC

1.02

0.82–1.25

0.853

 Center (frailty)

  

0.011

aGVHD III–IV

 MUD vs Haplo

1.52

0.85–2.71

0.154

 Year of Tx

0.97

0.91–1.03

0.369

 Age (per 10 years)

0.98

0.68–1.41

0.935

 Status at Tx

  CR ≥ 2 vs CR1

1.23

0.83–1.84

0.290

  Advanced vs CR1

1.78

1.31–2.43

< 10−4

 Cytogenetics

  Intermediate vs good

2.27

0.77–6.68

0.133

  Poor vs good

1.67

0.55–5.04

0.361

  Secondary vs good

2.03

0.73–5.67

0.173

  Missing vs good

1.69

0.61–4.70

0.311

 Female D/male R

1.02

0.69–1.51

0.895

 KPS ≥ 90%

0.68

0.52–0.91

0.009

 PBSC vs BM

1.20

0.71–2.02

0.478

 In vivo TCD

0.63

0.46–0.86

0.004

 Previous autograft

2.07

1.03–4.15

0.039

 RIC vs MAC

0.76

0.53–1.09

0.147

 Center (frailty)

  

0.054

cGVHD

 MUD vs Haplo

1.22

0.84–1.75

0.281

 Year of Tx

0.97

0.94–1.01

0.228

 Age (per 10 years)

0.99

0.80–1.23

0.964

 Status at Tx

  CR ≥ 2 vs CR1

1.05

0.84–1.30

0.669

  Advanced vs CR1

1.12

0.92–1.37

0.251

 Cytogenetics

  Intermediate vs good

1.72

1.01–2.91

0.042

  Poor vs good

1.74

1.01–2.99

0.045

  Secondary vs good

1.88

1.14–3.10

0.013

  Missing vs good

1.66

1.01–2.72

0.043

 Female D/male R

1.02

0.81–1.28

0.860

 KPS ≥ 90%

1.09

0.91–1.31

0.310

 PBSC vs BM

1.48

1.08–2.03

0.013

 In vivo TCD

0.57

0.47–0.70

< 10−4

 Previous autograft

1.64

0.99–2.70

0.050

 RIC vs MAC

0.82

0.67–1.02

0.077

 Center (frailty)

  

0.001

Extensive cGVHD

 MUD vs Haplo

2.02

1.17–3.47

0.011

 Year of Tx

0.97

0.92–1.02

0.298

 Age (per 10 years)

1.05

0.77–1.42

0.740

 Status at Tx

  CR ≥ 2 vs CR1

0.92

0.67–1.26

0.618

  Advanced vs CR1

0.97

0.73–1.30

0.874

 Cytogenetics

  Intermediate vs good

1.15

0.56–2.37

0.693

  Poor vs good

1.39

0.67–2.90

0.371

  Secondary vs good

1.27

0.64–2.49

0.481

  Missing vs good

1.11

0.57–2.16

0.751

 Female D/male R

0.94

0.66–1.34

0.751

 KPS ≥ 90%

1.00

0.77–1.29

0.997

 PBSC vs BM

1.30

0.83–2.05

0.245

 In vivo TCD

0.35

0.27–0.46

< 10−4

 Previous autograft

1.19

0.54–2.60

0.658

 RIC vs MAC

0.74

0.54–1.01

0.060

 Center(frailty)

  

0.022

  1. Abbreviations: LFS, leukemia-free survival; OS, overall survival; RI, relapse incidence; NRM, non-relapse mortality; GRFS, graft-versus-host-free-relapse free survival; a, acute; c, chronic; GVHD, graft versus host disease; MUD, matched unrelated donor; Haplo, haploidentical; Tx, transplant; CR, complete remission; KPS, Karnofsky performance status; PBSC, peripheral blood; BM, bone marrow; D, donor; R, recipient; TCD, T cell depletion; RIC, reduced intensity conditioning; MAC, myeloablative conditioning
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us